

Condensed Interim Consolidated Financial Statements

For the Three and Six Months Ended June 30, 2024 and 2023

Prepared by Management

(Expressed in U.S. dollars)

LIBERTY DEFENSE HOLDINGS, LTD.

Condensed Interim Consolidated Financial Statements

For the Three and Six Months Ended June 30, 2024 and 2023

NOTICE OF NO AUDITOR REVIEW

The accompanying unaudited condensed interim consolidated financial statements of Liberty Defense Holdings Ltd, (the "Company") have been prepared by and are the responsibility of Company's management and approved by the Company's Audit Committee and Board of Directors.

Pursuant to National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

August 15, 2024

Liberty Defense Holdings, Ltd. Condensed Interim Consolidated Statements of Financial Position

(Expressed in U.S. dollars)

Unaudited - Prepared by Management

As at:	Note	June 30, 2024	December 31, 2023
		\$	\$
Assets			
Current assets:			
Cash		175,467	963
Accounts receivable, prepaids and deposits	4	968,835	257,885
Inventory	5	541,160	1,255,077
Lease receivable	10	-	7,048
		1,685,462	1,520,973
Non-current assets:			
Property and equipment	6	884,296	1,043,876
Intangible assets	deposits 4 5 10 6 7 5 10 10 11 14 8 10 10 10 10 10 10 10 10 10	2,800,637	3,266,803
		3,684,933	4,310,679
Total assets		5,370,395	5,831,652
Liabilities			
Current liabilities:			
Accounts payable and accrued liabilities		3,247,672	3,862,675
Loans payable	8	633,858	530,062
Factoring liability		992,593	1,107,347
Deferred revenue	-	1,965,970	180,000
CEBA loan		29,269	29,445
Lease liabilities	-	251,469	247,412
	10	7,120,831	5,956,941
Non-current liabilities:		.,0,001	0,000,011
Non-current lease liabilities	10	548,749	639,173
Total liabilities		7,669,580	6,596,114
Shareholders' deficiency			
Share capital	11	34,287,085	32,565,254
Share subscriptions received in advance		508,864	224,915
Equity reserves		4,452,933	4,146,489
Accumulated other comprehensive loss		(71,480)	(221,071)
Deficit		(41,476,587)	(37,480,049)
Total shareholders' deficiency		(2,299,185)	(764,462)
Total liabilities and shareholders' deficiency		5,370,395	5,831,652

Nature of operations and going concern (note 1) Subsequent events (note 21)

Approved by the Board of Directors on August 15, 2024, and signed on the Company's behalf by:

"William Frain"	"Daryl Rebeck"
Director	Director

Liberty Defense Holdings, Ltd. Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Expressed in U.S. dollars) Unaudited - Prepared by Management

	Note	Th	ree months e			Six months e	
			2024		2023	<u>2024</u> \$	<u>2023</u> \$
						Ψ	φ
Revenue	14 & 15	\$	948,532	\$	432,407	1,580,588	943,978
Cost of revenue			1,852,111		299,744	2,339,529	645,954
Gross (loss) income			(903,579)		132,663	(758,941)	298,024
Engineering and Research and Development Expenses:							
Product development & technology Costs			122,686		259,532	163,396	310,058
Salaries and consulting fees	17		482,403				,
•			,		848,833	746,282	1,633,860
Stock-based compensation	12 & 17		29,307		20,344	53,404	47,402
Depreciation	6		68,577		131,467	150,341	313,294
Amortization	7		-		168,511	-	327,147
Office, rent & administration, travel and miscellaneous			41,229		52,857	50,905	164,691
General and Administration Expenses:							
Salaries and consulting fees	17		589,577		412,650	880,462	857,792
Legal and professional fees			85,422		147,485	141,304	173,463
Stock-based compensation	12 & 17		145,487		173,035	159,291	366,563
Office, rent & administration, travel, and miscellaneous			(125,920)		456,251	437,264	748,050
			1,438,768		2,670,965	2,782,649	4,942,320
Other expense (income):							
Other income, net of expenses			_		(1,103)	_	(1,103)
Interest expense			270,021		21,899	445,211	40,727
Accretion expense	8		270,021		582		(1,175)
Foreign exchange loss	0		6,254		201	9,737	201
			276,275		21,579	454,948	38,650
Net loss for the period		\$	(2,618,622)	\$	(2,559,881)	(3,996,538)	(4,682,946)
Other comprehensive loss							
Items that may be reclassified subsequently to profit or (loss)							
Foreign currency translation adjustment			139,077		(49,579)	149,591	(71,347)
Total loss and comprehensive loss for the period		\$		\$	(2,609,460)	(3,846,947)	(4,754,293)
		Ψ	(2,473,040)	Ψ	(2,003,400)	(0,040,047)	(4,704,200)
Weighted average number of common shares outstanding							
Basic and diluted			170 406 110		122 007 024	159 214 216	120 120 202
			170,496,112		123,997,831	158,214,216	120,438,393
Loss per share							
Basic and diluted loss per share	13	\$	(0.02)	ሰ	(0.02)	(0.03)	(0.04)

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency)

(Expressed in U.S. dollars, except number of shares)

Unaudited - Prepared by Management

	Note	Number of common shares	Share capital	Equity reserves	Share subscriptions received in advance	Accumulated other comprehensive income (loss)	Deficit	Total
		#	\$	\$	\$	\$	\$	\$
Balance as at December 31, 2022		116,839,406	28,936,296	3,518,365	-	(252,669)	(28,111,006)	4,090,986
Issue of private placement, net of share issue cost	11	10,261,061	1,395,357	_	_	_	_	1,395,357
Fair value of compensation broker warrants	11	_	(12,238)	12,238	_	_	_	_
Residual value allocated to warrants	11	_	(94,101)	94,101	_	_	_	_
Fair value of expired broker warrants	11	_	404,799	(404,799)	_	_	_	_
Stock based compensation	12	_	_	413,965	-	-	_	413,965
Foreign currency translation adjustment		_	_	_	-	(71,347)	_	(71,347)
Loss for the period		-	-	-	_	-	(4,682,946)	(4,682,946)
Balance as at June 30, 2023		127,100,467	30,630,113	3,633,870	-	(324,016)	(32,793,952)	1,146,015
Balance as at December 31, 2023		145,428,102	32,565,254	4,146,489	224,915	(221,071)	(37,480,049)	(764,462)
Issue of private placement, net of share issue cost	11	15,991,572	1,703,848	10,265	283,949	_	_	1,998,062
Residual value allocated to warrants	11	_	(426,662)	426,662	_	_	_	_
Restricted share units exercised	11	50,000	44,461	(44,461)	_	_	_	_
Warrants exercised	11	_	87,367	_	-	-	_	87,367
Stock based compensation	12	_	_	226,795	_	_	_	226,795
Fair value of warrants allocated to share capital on expiry	12	_	312,816	(312,816)	_	_	_	_
Foreign currency translation adjustment		_	_	·	_	149,591	_	149,591
Loss for the period		-	-	-	_	-	(3,996,538)	(3,996,538)
Balance as at June 30, 2024		161,469,674	34,287,085	4,452,933	508,864	(71,480)	(41,476,587)	(2,299,185)

Liberty Defense Holdings, Ltd. Condensed Interim Consolidated Statements of Cash Flows

(Expressed in U.S. dollars) Unaudited - Prepared by Management

	Note		ended June 30,
		<u>2024</u> \$	2023 \$
Cash (used in) provided by:		Φ	φ
Operating activities:			
Loss and comprehensive loss for the period		(3,996,538)	(4,682,946)
Items not involving cash:		(-,,	()
Lease liability interest	10	36,745	40,185
Accrued interest loans payable	8	21,159	-
Accretion expense CEBA loan	8	885	(1,175)
Depreciation	6	150,341	313,294
Depreciation recorded in cost of revenue	Ū	75,150	-
Amortization	7		327,147
Amortization recorded in cost of revenue	14 & 15	466,166	-
Loss on disposal of property and equipment	6	29,233	-
Stock based compensation	12	212,695	413,965
Stock based compensation in cost of revenue	12	14,099	-
Impairment of inventory	5	213,170	_
Accrued factoring fees	9	258,667	_
Changes in non-cash working capital:	5	200,001	
Amounts receivable and prepaids		(710,950)	(92,605)
Inventory		500,747	(536,530)
Accounts payable and accrued liabilities		(615,003)	2,935,126
Deferred revenue		1,785,970	2,333,120
Cash used in operating activities		(1,557,464)	(1,283,539)
nvesting activities:			<i>/</i>
Additions to intangible assets	7	_	(237,844)
Additions to property and equipment	6	(95,144)	(107,710)
Cash used in investing activities		(95,144)	(345,554)
Financing activities:			
Proceeds from issuance of units, net of share issue costs	11	1,998,063	1,395,357
Repayments on factoring	9	(373,421)	-
Proceeds from loans	8	517,525	-
Repayments of loans	8	(429,896)	-
Repayment of CEBA loan	8	(852)	-
Warrants exercised	11	87,367	-
Lease payments received	10	7,010	10,552
Repayment of leases	10	(123,112)	(117,465)
Cash provided by financing activities		1,682,684	1,288,444
Effect of foreign exchange rate changes on cash		144,428	(70,876)
Effect of foreign exchange rate changes on cash		144,428	(70,876)
		177,720	(10,010)
ncrease (decrease) in cash		174,504	(411,525)
Cash, beginning of the period		963	677,473
Cash, end of the period		175,467	265,948
During the six months ended June 30, 2024 and 2023, the Cor and \$nil in interest respectively.	mpany paid \$nil ar	nd \$nil in income taxes, ar	nd paid \$17,071
Supplemental cash flow information			
Fair value of compensation brokers warrants	11 \$	10,265 \$	12,238
Residual value allocated to warrants	11	426,662	_

Fair value of compensation brokers warrants	11	\$ 10,265	\$ 12,238
Residual value allocated to warrants	11	426,662	-
RSUs exercised	11	44,461	-
Reclassification from reserves upon warrant exercised	11	87,367	-
Fair value of warrants allocated to share capital on expiry	11	(312,816)	-

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

1. Nature of operations and going concern

Liberty Defense Holdings, Ltd. ("Liberty" or the "Company"), is a public company (TSXV: SCAN, Frankfurt: L2D, OTCQB: LDDFF), that was incorporated under the Business Corporation Act of Ontario on June 8, 2012. The Company's registered and records office is registered at 1055 West Georgia Street, 1500 Royal Centre, P.O. Box 11117. Vancouver, British Columbia, V6E 4N7, Canada.

The Company is principally engaged in the production and commercialization of an active 3D imaging technology system, HEXWAVE, to detect concealed threats.

Going concern

These condensed interim consolidated financial statements have been prepared using IFRS Accounting Standards as issued by the International Accounting Standards Board applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. The Company incurred in a total loss during the six months ended June 30, 2024, of \$3,996,538 and cash outflows from operating activities of \$1,557,464. To continue the early production and commercialization of HEXWAVE, the Company requires additional funds. These funds will be pivotal in advancing the production of HEXWAVE. Additionally, the Company has certain committed development milestones over the next twelve months and based on the Company's current forecasted operational and development spend, the Company will require additional funds to meet these milestones. While the Company has been successful in arranging financing in the past, the success of such initiatives cannot be assured. This material uncertainty casts significant doubt upon the Company's ability to continue as a going concern.

There are many external factors that can adversely affect global workforces, economies, and financial markets globally such as global health conditions and political conflict in other regions. It is not possible for the Company to predict the duration or magnitude of the adverse results of these factors and its effects on the Company's business or ability to raise funds.

These condensed interim consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and balance sheet classifications that would be necessary were the going concern assumption deemed to be inappropriate. These adjustments could be material.

2. Basis of presentation

(a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

These condensed interim consolidated financial statements were approved for issuance by the Board of Directors on August 15, 2024.

(b) Basis of measurement

These condensed interim consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments which are measured at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

(c) Functional and presentation currency

The functional currency of the Company is the Canadian dollar, and the presentation currency of these consolidated financial statements is the U.S. dollar ("USD"); therefore, references to \$ means USD and CAD\$ are to Canadian dollars.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

2. Basis of presentation (continued)

(d) Basis of consolidation

These condensed interim consolidated financial statements include the financial statements of Liberty Defense Holdings, Ltd., and the entities controlled by the Company (its subsidiaries), as follows:

Subsidiary	Place of Incorporation	Functional Currency	Beneficial Interest
Liberty Defense Technologies, Inc.	United States	USD	100%
DrawDown Detection, Inc.	Canada	CAD	100%
DrawDown Technologies, Inc.	United States	CAD	100%

Control exists when the Company has power over an investee, exposure, or rights, to variable returns from its involvement with the investee and the ability to use its power over the investee to affect the amount of the Company's returns. All intercompany balances and transactions have been eliminated upon consolidation.

(e) Critical accounting estimates and judgments

The preparation of financial statements in conformity with IFRS, requires management to select accounting policies and make estimates and judgments that may have a significant impact on the condensed interim financial statements. Estimates are continuously evaluated and are based on management's experience and expectations of future events that are believed to be reasonable under the circumstances. Actual outcomes may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

The Company's critical accounting judgements and estimates were presented in Note 3 of the annual audited consolidated financial statements and have been consistently applied in the preparation of these condensed interim consolidated financial statements. No new estimates and judgements were applied for the period ended June 30, 2024.

3. Material Accounting Policies

These condensed interim consolidated financial statements do not include all note disclosures required by IFRS for annual financial statements and, therefore, should be read in conjunction with the audited annual financial statements for the year ended December 31, 2023. In the opinion of management, all adjustments considered necessary for fair presentation of the Company's financial position, results of operations and cash flows have been included. Operating results for the three and six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

The following new standards and amendments to standards and interpretations, which become effective for current periods.

- a) Amendments to IAS 1 Classification of Liabilities as Current or Non-current. The amendment clarified the guidance on whether a liability should be classified as either current or non-current. The amendments are applied retrospectively for annual periods beginning on or after January 1, 2024.
- b) Amendments to IFRS 16 Lease liability in a Sale and Leaseback. The amendment clarifies how a seller-lessee subsequently measures sale and leaseback transactions that satisfy the requirements in IFRS 15 to be accounted for as a sale. These amendments are effective for annual periods beginning on or after January 1, 2024.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

3. Material Accounting Policies (continued)

c) Amendments to IAS 7 – Requiring entities to provide qualitative and quantitative information about their supplier finance arrangements. In connection with the amendments to IAS 7, the IASB also issued amendments to IFRS 7 requiring entities to disclose whether they have accessed, or have access to, supplier finance arrangements that would provide the entity with extended payment terms or the suppliers with early payment terms. These amendments are effective on January 1, 2024

The Company did not encounter any material effects from the implementation of new standards or amendments as at June 30, 2024.

4. Accounts Receivables, Prepaids and Deposits

	June 30,	December 31,
	2024	2023
Accounts receivables	\$ 881,370 \$	25,494
Prepaids and deposits	87,465	232,391
	\$ 968,835 \$	257,885

5. Inventory

	June 30,	December 31,
	2024	2023
Raw materials	\$ 422,326 \$	734,824
Work-in-progress	118,834	467,940
inished Goods	-	52,313
	\$ 541,160 \$	1,255,077

The Company reclassified finished goods inventory of \$nil (December 31, 2023, \$86,556) to property and equipment related to a HEXWAVE prototype unit. The HEXWAVE unit will be used in live scenarios to promote the product and collect data to further improve HEXWAVE. The Company reclassified work in process assemblies of \$48,185 (December 31, 2023, \$nil) to property and equipment related to the engineering prototype HEXWAVE unit. The engineering prototype HEXWAVE unit was disassembled and upgraded to be used for testing and development of enhanced algorithms.

As of June 30, 2024, the Company recorded an inventory impairment expense of \$213,170 (June 30, 2023 - \$nil).

As of June 30, 2024, the Company expensed \$989,607 of inventory to cost of sales (June 30, 2023, \$nil).

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

6. **Property and Equipment**

	Leasehold Improvement Equipment Right of Use Asset		Leasehold Improvement				Prototype	Constructi Pre	on in ocess	Total
Cost										
At December 31, 2022		\$6,735		\$222,954	\$ 772,312	\$ 584,859	\$ 88	715	\$ 1,675,575	
Additions		-		-	414,562	86,556	134	389	635,507	
Transfers		-		-	-	171,899	(171	,899)	-	
At December 31, 2023	\$	6,735	\$	222,954	\$ 1,186,874	\$ 843,314	\$ 51	205	\$ 2,311,082	
Additions		-		12,807	-	48,185	34	152	95,144	
Disposals		-		-	-	(116,933)		-	(116,933)	
At June 30, 2024	\$	6,735	\$	235,761	\$ 1,186,874	\$ 774,566	\$ 85	357	\$ 2,289,293	
Accumulated Depreciation										
At December 31, 2022		\$6,735		\$71,717	\$ 234,982	\$ 360,662	\$	-	\$ 674,096	
Depreciation for the year	-			59,059	192,581	341,529		-	593,169	
At December 31, 2023	\$	6,735	\$	130,776	\$ 427,563	\$ 702,191	\$	-	\$ 1,267,265	
Depreciation for disposal		-		-	-	(87,700)		-	(87,700)	
Depreciation for the period		-		28,445	94,750	102,296		-	225,491	
At June 30, 2024	\$	6,735	\$	159,221	\$ 522,313	\$ 716,787	\$	-	\$ 1,405,056	
Foreign exchange movement										
At December 31, 2023	\$	-	\$	-	\$ 59	\$ -	\$	-	\$ 59	
At June 30, 2024	\$	-	\$	-	\$ 59	\$ -	\$	-	\$ 59	
Net Book Value										
At December 31, 2023	\$	-	\$	92,178	\$ 759,370	\$ 141,123	\$ 51	205	\$ 1,043,876	
At June 30, 2024	\$	-	\$	76,540	\$ 664,620	\$ 57,779	\$ 85	357	\$ 884,296	

On February 1, 2023, the Company entered into a new office lease agreement for a period of thirty-six months whereby an initial right-of-use asset was recognized totaling \$58,386, using a 9.68% implicit interest rate.

On February 1, 2023, the Company entered into a new office lease agreement for a period of thirty-six months whereby an initial right-of-use asset was recognized totaling \$356,176, using a 9.81% implicit interest rate. The term of the additional lease is sixty-three months whereby an initial right-of-use asset was recognized on the commencement date of February 1, 2023.

During the six months ended June 30, 2024, equipment depreciation recorded to cost of sales was \$75,150 (six months ended June 30, 2023, \$nil). During the six months ended June 30, 2024, the Company disposed of assets with a carrying value of \$29,233 for \$nil proceeds (June 30, 2023, \$nil).

7. Intangible Assets

The continuity of the Company's intangible assets is as follows:

	Ν	AIT licenses	Battelle license		Intellectual property	Total	
Balance, December 31, 2022	\$	441,225	\$	59,430	\$	3,229,808 \$	3,730,463
Additions		-		231,805		-	231,805
Amortization		(34,108)		(67,985)		(593,372)	(695,465)
Balance, December 31, 2023	\$	407,117	\$	223,250	\$	2,636,436 \$	3,266,803
Additions		-		-		-	-
Amortization		(17,054)		(105,810)		(343,302)	(466,166)
Balance, June 30, 2024	\$	390,063	\$	117,440	\$	2,293,134 \$	2,800,637

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

7. Intangible Assets (continued)

Intangible assets included as MIT licenses and Battelle licenses include payments in connection to reimbursement of global patent filing costs and annual maintenance fees. Additionally, intellectual property was generated through the reverse take over ("RTO") transaction closed during the year ended December 31, 2021, and became ready for use during the year ended December 31, 2022. The remaining useful life of the intangible assets are as follows: MIT license 11.5 years, Battelle license nine months, and intellectual property 4.5 years. During the six months ended June 30, 2024, \$466,166 of amortization was allocated to cost of sales (six months ended June 30, 2023, \$nil).

(a) MIT License Agreements

The Company, through its wholly owned subsidiary Liberty Defense Technologies Inc. ("LDT"), has entered into agreements with the Massachusetts Institute of Technology ("MIT") and MIT's Lincoln Laboratory ("MIT LL"), including an exclusive patent licence agreement between MIT and LDT dated September 10, 2018, as amended from time to time (the "Licence Agreement"), a technology transfer agreement between LDT and MIT LL, effective August 24, 2018 (the "Technology Transfer Agreement"), and a cooperative research and development agreement between LDT and MIT dated as of December 21, 2018 ("CRADA"), such agreements providing LDT with an exclusive licence for patents, design assets and MIT LL technical expertise related to active three-dimensional imaging technology that are the core technology behind the HEXWAVE product.

The obligations under the Technology Transfer Agreement and the CRADA have now been completed. Liberty may consider extending the CRADA (and therefore changing its scope) if it determines that additional MIT LL technical expertise related to active three-dimensional imaging technology is required. Pursuant to the License Agreement, LDT has been granted the exclusive rights to MIT's patent in "multistatic sparse array topology for FFT-based field imaging" (MIT Case No. 1 8409L) (the "Patent"), which is being utilized in the development and application of the HEXWAVE product. The License Agreement is to be in effect until the expiration of the Patent, which is 11 years (December 2035). In granting LDT such patent rights, the Company shall pay MIT in addition to patent filling costs an annual maintenance fees as follows: 1) \$20,000 for 2019 (paid); \$50,000 for 2020 (paid); \$60,000 for 2021 (paid); \$100,000 for 2022 (paid); \$nil for 2023, \$40,000 for 2024, \$200,000 for 2025, and \$350,000 for 2026 and thereafter; and 2) a royalty of 5.7% of all future net sales of the Company. As at June 30, 2024, the Company accrued royalty payments of \$55,839 (December 31, 2023, \$nil). The Company shall also be required to achieve certain milestones.

(b) Battelle Memorial License Agreement

On March 22, 2021, the Company, through its wholly owned subsidiary DrawDown Detection, Inc. has entered into an agreement ("Battelle License Agreement") with Battelle Memorial Institute ("Battelle"), which operates the Pacific Northwest National Laboratory ("PNNL"), to license the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies. The agreement, as amended from time to time, provides the Company with a three-year exclusive license for certain patents which will convert to a non-exclusive license for the remaining life of the patents. The agreement also provides the Company with non-exclusive license for certain patents for life.

As consideration for the Battelle License Agreement, the Company paid \$30,000 upon signing and \$30,000 six months after.

Under the Battelle License Agreement, the Company shall pay a five percent royalty on net sales and a twenty-five percent royalty on all sublicensing revenues if permitted under the contract guidelines. Any government entity that has revenues would not require a five percent royalty on the net sales. As at June 30, 2024, the Company accrued no royalty payments (December 31, 2023, \$nil). The Company is also required to pay a minimum royalty amount as follows, unless the agreement is terminated:

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

7. Intangible Assets (continued)

(b) Battelle Memorial License Agreement (continued)

	Amounts
Year 2021 (paid)	\$ 50,000
Year 2022 (paid)	50,000
Year 2023 (payable)	100,000
Year 2024 and each year thereafter (payable)	200,000

The Company is obligated to achieve certain milestones in the next fifteen months and reimburse Battelle for ongoing patenting expenses, as well as past patenting expenses in the total amount of \$50,000, from which \$50,000 has been paid.

8. Loans Payable

(a) Related Party Loans

During the six months ended June 30, 2024, and fiscal year ended December 31, 2023, the Company received working capital loans from related parties. These loans, unsecured and non-interest bearing, lack specified maturity dates. Repayments will be made as adequate financing becomes available to the Company.

	Amounts
Balance, December 31, 2022	\$ -
Additions	1,381,120
Repayments	(1,052,426)
Balance, December 31, 2023	\$ 328,694
Additions	82,000
Repayments	(214,072)
Balance, June 30, 2024	\$ 196,622

(b) Short Term Loans

Additionally, during the fiscal year ended December 31, 2023, the Company received a secured business line of credit from American Express, subject to a general security agreement on the Company's assets, with various draws. The interest rate on the amount withdrawn varied from 7.49% to 25.71% over a six-month term. The monthly payments fluctuated based on the amount withdrawn from the line of credit with amounts ranging from \$1,782 to \$10,624 per month. The loan is set to mature on June 25, 2024. As of June 30, 2024, the loan has been paid and full.

During the fiscal year ended December 31, 2023, the Company received an unsecured business line of credit with BlueVine Capital for a twenty-six-week term with an interest rate of 1.10% and weekly payments of \$3,906. The loan is set to mature on June 5, 2024. As of June 30, 2024, the loan has been paid in full.

During the fiscal year ended December 31, 2023, the Company received a secured business line of credit with Headway Capital, subject to a general security agreement of the Company's assets, with one draw for a period of seventeen-months with a monthly interest rate of 4.17%. The Company makes monthly payments of \$6,021. The loan matures on January 31, 2025.

During the six months ended June 30, 2024, the Company received a secured business loan with Blade Funding for a thirty-two-week term with an interest rate of 11.50% and weekly payments of \$13,125. The loan is set to mature on January 19, 2025.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

8. Loans Payable (continued)

(b) Short Term Loans (continued)

Amounts
\$ -
332,596
30,312
(161,540)
\$ 201,368
435,525
21,158
(220,815)
\$ 437,236
\$

(c) CEBA Loan

The Company acquired a CAD\$40,000 Canada Emergency Business Account Ioan ("CEBA") on May 5, 2020, carrying a 0% interest rate until January 18, 2024 ("Term Period"). This Ioan was utilized to cover payroll, rent, and utilities as per the Ioan agreement guidelines. According to the terms, if 75% of the advanced amount is repaid before the Term Period, the remaining 25% is forgiven.

The Company failed to repay the CEBA loan by the Term Period resulting in its conversion to a term facility, with interest accruing at 5% per annum on the current outstanding balance at June 30, 2024 of \$29,269 (December 31, 2023, \$29,445). The CEBA loan will now have the principal amount due by December 31, 2026 ("Extension Period").

The net present value of the CEBA loan as of December 31, 2023, is \$29,445 and was presented as a current liability. The Company also recognized an accretion income of \$nil for the period ended June 30, 2024 (June 30, 2023, \$(1,175)).

9. Factoring Liability

On June 22, 2023, the Company engaged in a factoring arrangement with Bengal Capital, Inc. (the "Factor"). Per the agreement, the Company submits invoices or purchase orders to the Factor after credit approval, receiving 80% of the gross amount. The Factor assumes ownership of these accounts with full recourse. Furthermore, the Company is subject to a 4% monthly factoring fee based on the face value of the accounts. No collateral is used per the agreement; however, the Company is obligated to pay the balance regardless of receiving payment for advanced orders. During the six months ended June 30, 2024, the Company received funds of \$nil and incurred factor fees of \$258,667 with repayments of \$373,421. During the comparative period, June 30, 2023, the Company received funds of \$nil and incurred factor fees of \$11 and incurred factor fees of \$12,000 (December 31, 2023, \$nil).

The factoring liability as at June 30, 2024 and December 31, 2023 is as follows:

	Amounts
Balance December 31, 2022	\$ -
Additions	1,265,132
Factoring Fee	192,185
Repayments	(349,970)
Balance, December 31, 2023	\$ 1,107,347
Factoring Fee	258,667
Repayments	(373,421)
Balance, June 30, 2024	\$ 992,593

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

9. Factoring Liability (continued)

For accounting purposes, the factored trade receivable remains recorded in trade receivables, while the financing costs are amortized over the financing period.

10. Leases

The Company's lease liabilities as at June 30, 2024, and December 31, 2023, are as follows:

	Right of use liab
Balance, December 31, 2022	\$ 638,3
Additions	414,5
Finance costs	81,0
Lease payments	(247,1
Foreign exchange movement	(1
Balance, December 31, 2023	\$ 886,5
Finance costs	36,7
Lease payments	(123,1
Balance, June 30, 2024	\$ 800,2
Less current portion	251,4
Non-current lease liability	\$ 548,7

During the six months ended June 30, 2024, the Company recorded a lease expense of \$nil (six months ended June 30, 2023 – \$23,317) related to short-term leases not meeting the criteria for capitalization under IFRS 16.

Minimum lease payments are as follows:

	June 30, 2024	December 31, 2023
Maturity analysis - contractual undiscounted cash flows		
One year or less	\$ 251,469 \$	247,412
Two to five years	688,651	815,820
Six and thereafter	-	-
Total lease liabilities	\$ 940,120 \$	1,063,232
Effect of discounting	(139,902)	(176,647)
Lease liabilities included in the statement of financial position	\$ 800,218 \$	886,585
Current	\$ 251,469 \$	247,412
Non-current	\$ 548,749 \$	639,173

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

10. Leases (continued)

The Company's lease receivable balances as at June 30, 2024, and December 31, 2023, are as follows:

	Amounts
Balance, December 31, 2022	\$ 26,837
Accretion	983
Payments received	(20,827)
Foreign exchange movement	55
Balance, December 31, 2023	\$ 7,048
Accretion	80
Payments received	(7,010)
Foreign exchange movement	(118)
Balance, June 30, 2024	\$ -
Less current portion	_
Non-current lease receivable	\$ _

As a result of the completion of the RTO in March 2021, the Company's head office was moved to Boston, MA. Therefore, the previous head office space was subleased until the expiry of the headlease (April 2024). The Company fair valued the lease receivable by present valuing the expected lease receivable payments over the life of the lease. The Company used an interest rate of 5.55%, the interest rate implicit in the lease. Minimum undiscounted sublease payments receivable is: \$nil.

11. Share Capital

(a) Common share transactions for the six months ended June 30, 2024

i) On January 15, 2024, the Company closed the initial tranche of a Listed Issuer Financing Exemption (LIFE) private placement of units, raising gross proceeds of \$662,554 (CAD\$886,000). As of December 31, 2023, the Company had received \$224,915 of these proceeds. This tranche involved the issuance of 5,900,663 units at a price of CAD\$0.15 per unit. Each unit consisted of one common share and one purchase warrant, allowing the holder to purchase an additional common share at CAD\$0.20 per share within 36 months. The warrants were allocated a residual value of \$154,596. Additionally, the Company issued 151,713 broker warrants to agents under identical terms and conditions with a fair value of \$4,508. Agent commissions totaling \$17,110 were paid. All securities issued are subject to a hold period expiring four months and one day after the closing date of the private placement.

Subsequently, on February 7, 2024, the Company closed the final tranche of the same non-brokered private placement, raising an additional \$112,285 (CAD\$150,000). This tranche involved the issuance of 1,000,000 units under the same terms and conditions as the initial tranche. Each unit consisted of one common share and one purchase warrant, allowing the holder to purchase an additional common share at CAD\$0.20 per share within 36 months. The warrants were allocated a residual value of \$37,428.

- ii) On February 28, 2024, the Company closed an investment by Viken Detection Corp. ("Viken") pursuant to which Viken purchased 9,090,909 units of the Company at an issue price of CAD\$0.15 per unit for total gross proceeds of \$1,000,000 (CAD\$1,363,636). Each unit comprised one common share and one purchase warrant. Each warrant entitles Viken to purchase one additional common share of the Company at an exercise price of CAD\$0.20 for a period of 36 months. The warrants were allocated a residual value of \$166,667. Additionally, the Company also incurred cash costs in connection to filing and legal expenses in the amount of \$11,651 were also paid. These warrants contain blocker language restricting the exercise of the Company.
- iii) On March 17, 2024, a total of 1,996,363 finder warrants expired with an exercise price of CAD\$0.33. These broker warrants had a fair value at \$312,816 and the reserve value was reclassified to share capital.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

11. Share Capital (continued)

(a) Common share transactions for the six months ended June 30, 2024 (continued)

- iv) On March 22, 2024, a total of 50,000 common shares were issued pursuant to the exercise of RSUs with a fair value of \$8,371 (CAD\$11,363).
- v) On April 29, 2024, a total of 36,500 shares were issued pursuant to the exercise of 36,500 warrants, resulting in proceeds of \$5,346 (CAD\$7,300).
- vi) On May 1, 2024, a total of 12,500 shares were issued pursuant to the exercise of 12,500 warrants, resulting in proceeds of \$1,815 (CAD\$2,500).
- vii) On May 7, 2024, a total of 71,000 shares were issued pursuant to the exercise of 71,000 warrants, resulting in proceeds of \$10,377 (CAD\$14,200).
- viii) On May 8, 2024, a total of 480,000 shares were issued pursuant to the exercise of 480,000 warrants, resulting in proceeds of \$69,829 (CAD\$96,000).
- ix) On May 23, 2024, a total of 113,405 shares were issued pursuant to the exercise of 113,405 RSUs with a fair value of \$36,090 (CAD \$49,331).
- x) On June 27, 2024, the Company closed the first tranche of a special warrant financing for gross proceeds of \$508,864 (CAD\$697,550). The Company issued 4,650,000 special warrants of the Company at a price of CAD\$0.15 per Unit. Each special warrant will automatically convert into one Unit. Each Unit shall consist of one common share and one share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the Company at a price of CAD\$0.20 within a period of 36 months. The warrants were allocated a residual value of \$67,971. The Company paid the agents 190,150 broker warrants with a fair value of \$5,756. Each broker warrant will be exercisable to purchase one common share for a period of 36 months at an exercise price of CAD\$0.20. Additionally, the Company also incurred cash costs in connection to private placement in the amount of \$31,966. All securities issued under the private placement are subject to a hold period expiring four months and one day after the closing date of the private placement.

(b) Common share transactions for the six months ended June 30, 2023

- i) On March 11, 2023, a total of 1,098,125 finder warrants expired with an exercise price of CAD\$0.40. These broker warrants had a fair value at \$186,713 and the reserve value was reclassified to share capital.
- ii) On April 14, 2023, the Company closed the first tranche of a non-brokered private placement for gross proceeds of \$1,007,249 (CAD\$1,341,212). The Company issued 6,706,061 units (each a "Unit") of the Company at a price of CAD\$0.20 per Unit. Each Unit comprised of one common share and one-half share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the Company at a price of CAD\$0.30 within a period of 24 months. The warrants were allocated a residual value of \$53,595. The Company paid the agents 215,250 broker warrants with a fair value of \$5,464. Each broker warrant will be exercisable to purchase one common share for a period of 24 months at an exercise price of CAD\$0.30. Additionally, the Company also incurred cash costs in connection to private placement in the amount of \$93,430. All securities issued under the private placement are subject to a hold period expiring four months and one day after the closing date of the private placement.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

11. Share Capital (continued)

(b) Common share transactions for the six months ended June 30, 2023 (continued)

- iii) On May 9, 2023, the Company closed the second tranche of a non-brokered private placement for gross proceeds of \$296,940 (CAD\$397,000). The Company issued 1,985,000 units (each a "Unit") of the Company at a price of CAD\$0.20 per Unit. Each Unit comprised of one common share and one-half share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the Company at a price of CAD\$0.30 within a period of 24 months. The warrants were allocated a residual value of \$8,463. The Company paid the agents 138,950 broker warrants with a fair valued at \$4,881. Each broker warrant will be exercisable to purchase one common share for a period of 24 months at an exercise price of CAD\$0.30. Additionally, the Company also incurred cash costs in connection to private placement in the amount of \$20,803. The Company also issued 45,000 units for gross proceeds of \$6,732, which were issued in order to offset invoices due to a vendor. All securities issued under the private placement.
- iv) On June 8, 2023, the Company closed the third and final tranche of a non-brokered private placement for gross proceeds of \$228,547 (CAD\$305,000). The Company issued 1,525,000 units (each a "Unit") of the Company at a price of CAD\$0.20 per Unit. Each Unit comprised of one common share and one-half share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the Company at a price of CAD\$0.30 within a period of 24 months. The warrants were allocated a residual value of \$32,043. The Company paid the agents 92,750 broker warrants with a fair valued of \$1,893. Each broker warrant will be exercisable to purchase one common share for a period of 24 months at an exercise price of CAD\$0.30. Additionally, the Company also incurred cash costs in connection to filing and legal expenses in the amount of \$23,146. All securities issued under the private placement are subject to a hold period expiring four months and one day after the closing date of the private placement.
- v) On June 17, 2023, a total of 1,056,900 broker warrants expired with an exercise price of CAD\$0.50. These broker warrants had a fair value of \$218,086, and the reverse value was reclassified to share capital.

12. Equity Reserves

(a) Share-based compensation

The Company maintains an Omnibus Equity Incentive Plan (the "Incentive Plan") which is comprised of stock options, restricted share units ("RSUs") and deferred share units ("DSUs"). The maximum number of common shares reserved for issuance, in the aggregate, under the Incentive Plan is 10% of the aggregate number of common shares issued and outstanding to be granted to directors, officers, employees, and consultants under certain restrictions.

Unless the Board decides, or the grant agreement specifies otherwise, the stock options will vest in two years with quarterly intervals following the date of such grant. The Board shall fix the exercise price of any stock option when such stock option is granted, which shall not be less than the closing price of the common shares on the Exchange on the day prior to the date of grant (the "Market Value"). A stock option shall be exercisable during a period established by the Board, which shall commence on the date of the grant and shall terminate no later than ten (10) years after the date of grant of the award or such shorter period as the Board may determine.

With respect to RSUs, the specific provisions of the RSU plan, eligibility, vesting period, terms of the RSUs and the number of RSUs granted are to be determined by the Board of Directors at the time of the grant.

With respect to PSUs, the specific provisions of the PSU plan, eligibility, vesting period, terms of the PSUs and the number of PSUs granted are to be determined by the Board of Directors at the time of the grant.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

12. Equity Reserves (continued)

(a) Share-based compensation (continued)

The continuity of the number of stock options issued and outstanding are as follows:

	Number of stock options	Weighted average exercise price
Outstanding, December 31, 2022	5,654,597	CAD\$ 0.54
Cancelled	(210,000)	0.43
Granted	1,245,000	0.19
Outstanding, December 31, 2023	6,689,597	CAD\$ 0.48
Cancelled	(127,500)	0.45
Outstanding, June 30, 2024	6,562,097	CAD\$ 0.48

As at June 30, 2024, the number of stock options outstanding and exercisable were:

	Outstanding		Exercisable	
Expiry date	Number of stock options	Exercise price	Remaining contractual	Number of stock
			life (years)	options
1-Jul-24	75,000	CAD\$ 0.50	0.00	75,000
8-Jul-24	75,000	CAD\$ 0.50	0.02	75,000
31-Jul-24	50,000	CAD\$ 0.50	0.08	50,000
23-Aug-24	37,500	CAD\$ 0.50	0.15	37,500
25-Sep-24	37,500	CAD\$ 0.50	0.24	37,500
29-Sep-24	75,000	CAD\$ 0.50	0.25	75,000
Apr 9 and Jul 2, 2024	137,097	CAD\$ 4.96	0.01	137,097
7-Apr-26	1,550,000	CAD\$ 0.50	1.77	1,550,000
10-Jun-26	100,000	CAD\$ 0.50	1.95	100,000
28-Jul-26	125,000	CAD\$ 0.55	2.08	125,000
28-Jul-26	90,000	CAD\$ 0.65	2.08	90,000
1-Nov-26	465,000	CAD\$ 0.46	2.34	465,000
14-Jan-27	100,000	CAD\$ 0.36	2.54	100,000
26-Apr-27	1,795,000	CAD\$ 0.41	2.82	1,795,000
26-May-27	250,000	CAD\$ 0.50	2.90	250,000
26-May-27	125,000	CAD\$ 0.38	2.90	125,000
16-Aug-27	185,000	CAD\$ 0.29	3.13	161,875
21-Nov-27	60,000	CAD\$ 0.22	3.39	45,000
26-Apr-28	110,000	CAD \$0.18	3.82	55,000
16-Oct-28	1,120,000	CAD \$0.19	4.30	280,000
June 30, 2024	6,562,097			5,628,972

During the six months ended June 30, 2024, the Company recognized stock-based compensation related to stock options totaling 50,736 (six months ended June 30, 2023 - \$139,093). Of this amount, \$14,099 was recorded as stock-based compensation in the cost of revenue (six months ended June 30, 2023 - \$nil).

Subsequent to the six months ended June 30, 2024, the Company had 200,000 stock options expire.

The fair value of the stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

12. Equity Reserves (continued)

(a) Share-based compensation (continued)

	June 30,	December 31,	
	2024	2023	
Risk-free interest rate	-	4.16%	
Expected dividend yield	-	Nil	
Stock price volatility	-	80.98%	
Expected life (in years)	-	5 years	
Stock price	-	CAD\$0.11	

(b) Restricted share units ("RSU")

Restricted share units granted during the six months ended June 30, 2024:

- i) On February 28, 2024, the Company granted 1,475,000 RSUs to employees; these RSUs shall be settled with common shares of the Company, are restricted until February 28, 2029, and vest at 100% on February 28, 2025.
- ii) On March 25, 2024, a total of 50,000 common shares were issued pursuant to the exercise of RSUs.
- iii) On March 31, 2024, a total of 1,122,475 RSUs were canceled.
- iv) On May 23, 2024, a total of 113,405 common shares were issued pursuant to the exercise of RSUs.

No RSUs were granted during the six months ended June 30, 2023.

The following table summarizes the movements in outstanding RSUs:

	Number of equity settled RSUs	Deemed Grant Price
Outstanding, December 31, 2022	2,472,155	CAD\$ 0.50
Granted	3,456,975	0.17
Outstanding, December 31, 2023	5,929,130	CAD\$ 0.21
Granted	1,475,000	0.13
Cancelled	(1,122,475)	0.31
Exercised	(163,405)	0.22
Outstanding, June 30, 2024	6,118,250	CAD\$ 0.27

The estimated fair value of the equity settled RSUs granted as of June 30, 2024, was 141,187 (six months ended June 30, 2023 -snil) and will be recognized as an expense over the vesting period of the RSUs. The fair value of the equity settled RSUs as at the grant date was determined with reference to the market value of the common shares of the Company at the grant date.

During the six months ended June 30, 2024, the Company recognized stock-based compensation related to RSUs in the amount of 109,940 (six months ended June 30, 2023, - 168,915).

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

12. Equity Reserves (continued)

(c) Share purchase warrants

The continuity of the number of share purchase warrants outstanding is as follows:

	Warrants	Exercise
	outstanding	Price
Outstanding, December 31, 2022	46,917,380	CAD\$ 0.40
Issued	24,012,344	0.30
Expired	(17,910,025)	0.64
Outstanding, December 31, 2023	53,019,699	CAD\$ 0.40
Issued	20,983,795	0.17
Exercised	(600,000)	0.20
Expired	(17,977,269)	0.48
Outstanding, June 30, 2024	55,426,225	CAD\$ 0.28

The fair value of the compensation warrants was estimated using the Black-Scholes option valuation model with the following weighted average assumptions:

	June 30,	December 31,	
	2024	2023	
Risk-free interest rate	3.72%	3.53%	
Expected dividend yield	Nil	Nil	
Stock price volatility	66.71%	63.89%	
Expected life (in years)	3 years	2 years	
Share price on grant date	CAD\$0.12	CAD\$0.18	
Fair value share purchase warrants	CAD\$0.04	CAD\$0.04	

The outstanding number of share purchase warrants is as follows:

		Outstanding						
Expiry date	Number of warrants	Exercise price	Remaining contractual life (years)					
13-Apr-25	3,353,030	CAD\$0.30	0.79					
13-Apr-25	215,250	CAD\$0.30	0.79					
9-May-25	1,015,000	CAD\$0.30	0.86					
9-May-25	138,950	CAD\$0.30	0.86					
8-Jun-25	762,500	CAD\$0.30	0.94					
8-Jun-25	92,750	CAD\$0.30	0.94					
5-Oct-26	17,827,635	CAD\$0.30	2.27					
5-Oct-26	607,229	CAD\$0.20	2.27					
12-Jan-27	3,733,332	CAD\$0.20	2.54					
12-Jan-27	1,567,331	CAD\$0.20	2.54					
12-Jan-27	151,713	CAD\$0.20	2.54					
5-Feb-27	1,000,000	CAD\$0.20	2.60					
28-Feb-27	9,090,909	CAD\$0.15	2.67					
27-Oct-27	1,446,736	CAD\$0.28	3.33					
27-Oct-27	9,345,850	CAD\$0.50	3.33					
27-Oct-27	237,500	CAD\$0.50	3.33					
27-Jun-27	4,650,000	CAD\$0.15	2.99					
27-Jun-27	190,510	CAD\$0.15	2.99					
	55,426,225							

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

12. Equity Reserves (continued)

(d) Performance Shares

On March 17, 2021, Liberty deposited into escrow, and held in escrow, Operational Performance Shares ("OPS") and Capital Market Performance Shares ("CMPS") for certain directors, officers, and consultants of the Company upon the Company achieving certain performance milestones. Once these milestones were achieved the shares would be released. These performance shares included 2,000,000 of OPS and 8,773,000 of CMPS. In order to fair value these performance shares, management estimated the probability that the Company would issue the performance shares.

Operational Performance Shares

During the six months ended June 30, 2024, and 2023, none of the 2,000,000 OPS have been issued as neither of the two milestones have been met. The estimated fair value of the OPS is CAD\$800,000 which had an estimated vesting period between December 2024 and December 2025. During the six months ended June 30, 2024, the Company recorded stock-based compensation in connection to OPS in the amounts of \$66,119 (six months ended June 30, 2023, \$105,957).

	Number of equity	Weighted average		
	settled performance	price		
Outstanding, December 31, 2022 and 2023	2,000,000	CAD\$ 0.40		
Released from escrow	-	0.00		
Outstanding, June 30, 2024	2,000,000	CAD\$ 0.40		

Capital Market Performance Shares

During the year ended December 31, 2021, the Company issued 2,193,250 of the total 8,773,000 CMPS upon achieving one of the four established milestones. During the year ended December 31, 2022, an additional 6,579,750 CMPS were issued as the remaining three milestones were met. The Company estimated the probability of the number of CMPS to be issued and an estimated vesting period between June 2021 and September 2022. The total estimated fair value of the CMPS was \$2,696,688, which has been fully expensed.

13. Loss Per Share

Basic loss per share amounts is calculated by dividing the net loss for the year by the weighted average number of common shares outstanding during the period.

	Three	moi	nths ended June 30,	Six months	ended June 30,	
	2024		2023		2024	2023
Loss attributable to common shareholders	\$ (2,618,622)	\$	(2,559,881)	\$	(3,996,538) \$	(4,682,946)
Weighted average number of shares	170,496,112		123,997,831		158,214,216	120,438,393
Basic and diluted loss per share	\$ (0.02)	\$	(0.02)	\$	(0.03) \$	(0.04)

The Company incurred net losses for the three and six months ended June 30, 2024, and 2023, therefore all outstanding stock options share purchase warrants, restricted share units, and performance share units, if any, have been excluded from the calculation of diluted loss per share since the effect would be anti-dilutive.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

14. Revenue

Revenue recognition during the six months ended June 30, 2024, relates to the contract revenue (note 16) from the Transportation Security Administration ("TSA"), as well as HEXWAVE units sales.

As at June 30, 2024, accounts receivable for work completed on contract awards was 250,000 (December 31, 2023 - 1,202

Revenue	ue Three month			ended June 30,	Six mon	Six months ended June 30,		
		2024		2023		2024		2023
Battelle Contract Award	\$	-	\$	2,034	\$	-	\$	2,034
TSA Contract Award HD-AIT		-		425,000		200,000	\$	915,000
TSA OA Development		250,000		-		450,000		-
HD-AIT Phase II		-		-		133,056		-
TSA Hexwave		-		5,374		-		26,945
HEXWAVE units		698,532		-		797,532		
Total Revenue	\$	948,532	\$	432,407	\$	1,580,588	\$	943,978

15. Contract Awards

During the six months ended June 30, 2024, the Company recognized total contract revenue of 783,056 recorded in revenue (six months ended June 30, 2023, - \$943,978). Future revenues in connection with these contracts will be recognized as performance obligations are met. It is estimated that future revenues will be recognized under the same basis following these timelines:

Contract Award Revenue Expected	Year ended December 3						
_		2024		2025			
TSA Contract Award HD-AIT	\$	457,905	\$	-			
TSA OA Development		591,944		-			
Total estimated contract revenues	\$	1,049,849	\$	-			

(a) Battelle HD-AIT Shoe Scanner

On May 12, 2022, the Company received a contract award for \$212,697 from Battelle, Pacific Northwest Division's Contract. The contract award is to work hand in hand with PNNL to develop the High Definition – Advanced Imaging Technology ("HD-AIT") Retrofit Kits. On July 31, 2023, there was a contract modification decreasing the total allotment from \$212,697 to \$100,000. With developing the HD-AIT Retrofit Kits, the Battelle Memorial License and patent will be utilized in the HD-AIT technology development. The contract award was completed in fiscal year ended 2023 and has been closed. During the six months ended June 30, 2024, as part of the contract award the Company received \$nil and had a receivable of \$nil (June 30, 2023, \$nil and \$2,034).

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

15. Contract Awards (continued)

(b) TSA HD-AIT Upgrade

On September 30, 2022, the Company received a contract award for \$1,747,905 from Transportation Security Administration ("TSA") for the HD-AIT Wide Band Upgrade Kit. On September 28, 2023, the contract was modified adding an additional milestone. The new contract award with the modification is \$1,922,905. The contract award is to develop a series of millimeter-wave imaging system prototypes to advance and upgrade the current state-of-the-art imaging technology for the current passenger security screening applications. The project will be performed over a period of eighteen months, and invoices will be issued once the milestones are reached based on the agreed upon timeline. During the six months ended June 30, 2024, the Company received \$200,000 and had a receivable of \$nil (six months ended June 30, 2023, – \$740,000 and \$175,000). The balance remaining on the contract as of June 30, 2024, was \$357,905 (December 31, 2023, – \$657,905). The Company is required to submit quarterly invoices as follows:

TSA HD-AIT Upgrade	Amounts
Year 2023	\$ 1,265,000
Year 2024	
Milestone 5 A (Q1 2024) (payment received)	200,000
Milestone 5B (Q3 2024)	100,000
Milestone 6 (Q3 2024)	357,905
Total	\$ 1,922,905

(c) TSA Open Architecture

On September 29, 2023, the Company received a contract award for \$1,116,944 from TSA for the Open Architecture Development. The contract award is to develop a system-level approach that addresses TSA's request for implementation of a Checkpoint Open Architecture for On-Person Screening (OPS) systems that enable modularity and enhances security effectiveness. The project will be performed over a period of thirteen months, and invoices will be issued once the milestones are reached based on the agreed upon timeline. During the six months ended June 30, 2024, the Company received \$200,000 and had a receivable of \$250,000 (six months ended June 30, 2023, - \$nil and \$nil). The balance remaining on the contract as of June 30, 2024, was \$591,944 (December 31, 2023, - \$1,041,944). The Company is required to submit quarterly invoices as follows:

TSA Open Architecture	Amounts
Year 2023	\$ 75,000
Year 2024	
Milestone 2 (Q1 2024) (payment received)	200,000
Milestone 3 (Q2 2024) (invoiced)	250,000
Milestone 4 (Q3 2024)	170,000
Milestone 5 (Q3 2024)	175,000
Milestone 6 (Q4 2024)	175,000
Milestone 7 (Q4 2024)	71,944
Total	\$ 1,116,944

(d) TSA HD-AIT Phase I

On September 29, 2023, the Company received a contract award for \$133,056 from TSA for the HD-AIT Phase II. The contract award is a follow-on option to the current HD-AIT development program to execute phase II to drive to a final hardware design capable of supporting future compliance efforts. The project will be performed over a period of three months, and invoices will be issued once the milestones are reached based on the agreed upon timeline. During the six months ended June 30, 2024, the Company received \$133,056 and had a receivable of \$nil (six months ended June 30, 2023, - \$nil and \$nil). The balance remaining on the contract as of June 30, 2024, was \$nil, as the agreement was completed on February 20, 2024.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

16. Collaboration Agreements

Transportation Security Administration's ("TSA") On-Person Screening Capability Program

On October 20, 2021, the Company received a contract award for \$500,000 from TSA as part of the TSA On-Person Screening Capability Program. The contract award is for the demonstration and evaluation of the Company's HEXWAVE technology and its expanded capabilities for screening aviation workers to enhance detection and throughput performance. In order for the Company to draw down on this award, Liberty is required to have its HEXWAVE technology working at certain locations to collect and share data with TSA on identified threats to further develop algorithms to improve the recognition of threats with desire probability of detection. During the six months ended June 30, 2024, the Company received \$nil in connection with this award and had a receivable of \$nil (six months ended June 30, 2023, - \$21,571 and \$5,374). The balance remaining on the contract as of June 30, 2024, was \$nil, (December 31, 2023, \$nil) as the agreement was completed on November 30, 2023.

17. Related Party Transactions

Compensation of key management personnel:

Key management personnel include persons having the authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The key management personnel of the Company are the members of the Company's executive management team and Board of Directors. Compensation provided to key management personnel is as follows:

	Three months ended June 30,				Six mor	iths en	ded June 30,
	2024		2023		2024		2023
G&A Salaries	\$ 171,565	\$	239,596	\$	313,422	\$	476,239
G&A Stock-based compensation	84,127		150,513		420,475		310,315
G&A Consulting fees (1)	24,116		34,908		48,596		78,463
	\$ 279,809	\$	425,018	\$	782,493	\$	865,017

() Consulting fees were paid or payable to 1214852 B.C. LTD

As of June 30, 2024, the Company had a balance payable of 691,902 to key management personnel (December 31, 2023, - 614,547). This payable balance includes accounts payable and accrued liabilities relating to compensation to directors, officers, or their related companies, included in compensation of key management personnel. These related party balances are unsecured, non-interest bearing and have no specific terms of settlement.

During the six months ended June 30, 2024, the Company paid Nicole Ridgedale Communications, a related party to the Company an amount of \$23,340 (six months ended June 30, 2023, \$42,491) for consulting services and stock-based compensation. As at June 30, 2024 the balance owing to Nicole Ridgedale Communications is \$nil (December 31, 2023 - \$23,340). This related party balance is unsecured, non-interest bearing and have no specific terms of settlement.

During the six months ended June 30, 2024, the Company received working capital loans (note 8) in the amount of \$82,000 (six months ended June 30, 2023 - \$1,473,196) from directors, officers, or their related parties. As at June 30, 2024, the outstanding balance is \$196,623 (December 31, 2023 - \$328,694).

18. Financial Instruments

As at June 30, 2024, the Company's financial instruments comprise cash, accounts receivables, accounts payable and accrued liabilities, loans payable, factoring liability and the CEBA loan. The fair values of the Company's financial instruments approximate their carrying values due to their short-term maturity.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

18. Financial Instruments (continued)

Fair value of financial instruments:

Financial instruments recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The three levels of the fair value hierarchy are:

- · Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities.
- · Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly
- · Level 3 Inputs that are not based on observable market data.

The Company's activities expose it to financial risks of varying degrees of significance, which could affect its ability to achieve its strategic objectives for growth and shareholder returns. The principal financial risks to which the Company is exposed are credit risk, liquidity risk and currency risk. The Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework and reviews the Company's policies on an ongoing basis.

(a) Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations, including accounts receivable terms. The Company's cash is held through large Canadian, international, and foreign national financial institutions. The Company's receivables primarily consist of trade receivables that the Company continues to collect. These trade receivables are primarily with government agencies and are not subject to significant credit risk. The Company's maximum exposure to credit risk is limited to the carrying amount of cash and accounts receivables of \$1,056,838.

(b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure. To mitigate this risk, the Company has a planning and budgeting process in place to determine the funds required to support its ongoing operations and capital expenditures. The Company ensures that sufficient funds are raised from equity offerings or debt financings to meet its operating requirements, after considering existing cash balances, expected exercise of share purchase warrants, and stock options. The Company's ability to continue as a going concern involves significant judgements and estimates while determining forecasted cashflows and is dependent on the Company's ability to obtain financing (note 1). As at June 30, 2024, the Company had cash of \$175,467 (December 31, 2023 – \$963) to settle current liabilities of \$7,120,831 (December 31, 2023 – \$5,956,941). Most of the Company's financial liabilities have contractual maturities of 30 days or less and are subject to normal trade terms.

(c) Market risk

This is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Significant market risks to which the Company is exposed are as follows:

Interest rate risk

Interest rate risk arises from changes in market rates of interest that could adversely affect the Company. The Company currently has interest-bearing financial instruments in relation to loans and the factoring agreement (note 8 & 9). The Company's exposure to interest rate risk is minimal as the interest rates are at a fixed percentage on the term of the loan and factoring.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

18. Financial Instruments (continued)

(c) Market risk (continued)

Foreign currency risk

The Company is exposed to currency risk by having balances and transactions in currencies that are different from its functional currency. The Company operates in foreign jurisdictions, which uses the U.S. dollar. The Company does not use derivative instruments to reduce upward, and downward risk associated with foreign currency fluctuations.

	Amounts US dollars		
Financial assets denominated in foreign currencies Financial liabilities denominated in foreign currencies	\$ 1,429 (609,715)		
Net exposure	\$ (608,286)		

A 10% change in the U.S. dollar exchange rate relative to the Canadian dollar would change the Company's comprehensive loss by \$60,829.

Price risk

The Company is exposed to price risk with respect to equity prices. Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices or general movements in the level of the stock market.

The Company closely monitors individual equity movements, and the stock market to determine the appropriate course of action to be taken by the Company.

19. Capital Risk Management

The Company manages common shares, stock options, performance share units, restricted share units, and share purchase warrants as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its products and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, issue debt, acquire or dispose of assets, or adjust the amount of cash on hand.

In order to facilitate the management of its capital requirements, the Company prepares expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions.

In order to maximize ongoing development efforts, the Company does not pay out dividends. The Company's investment policy is to keep its cash treasury on deposit in an interest-bearing chartered bank account. Cash consists of cash on held with banks.

The Company expects its current capital resources will be sufficient to carry its operations, and product development plans for the foreseeable future. The Company is not subject to externally imposed capital requirements.

There has been no change to the Company's approach to capital management during the six months ended June 30, 2024.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited - Expressed in U.S. dollars, unless otherwise stated and per share amounts) For the three and six months ended June 30, 2024, and 2023

20. Geographic Information

The Company operates in one reportable operating segment, being the development and commercialization of new technology for the security industry.

As at June 30, 2024 and December 31, 2023, all non-current assets and liabilities are located in the United States.

All revenues earned during the six months ended June 30, 2024, and 2023 were generated in the United States.

21. Subsequent Events

On July 29, 2029, the Company signed an engagement agreement with Titan Partners, a venture capitalist, to be the exclusive financial advisor and underwriter in connection with an offering or series of offerings of the Company securities and the other matters.